Archives
Intravesical p21 mRNA–LNP Therapy for Bladder Cancer
2026-09-22
The reference study develops a localized, nonviral tumor-suppressor replacement strategy in which chemically modified p21 mRNA is encapsulated in lipid nanoparticles and administered intravesically. In an orthotopic mouse model, this approach restored p21 expression, altered cell-cycle and DNA-damage pathways, and suppressed bladder tumor growth while limiting systemic distribution.
Selonsertib (GS-4997) for Stress-Pathway Assays
2026-09-21
Selonsertib (GS-4997) enables selective ASK1 pathway interrogation in oxidative stress, inflammation, fibrosis, and metabolic disease models. This article develops an assay-design framework connecting ASK1 signaling with the Galectin-1–FIP200 autophagy axis without overstating evidence from hepatic steatosis studies.
Vorinostat: HDAC Inhibition in Cancer Research
2026-09-20
Vorinostat, also called suberoylanilide hydroxamic acid, is an HDAC inhibitor that increases histone acetylation and changes transcriptional programs. Its research value spans epigenetic modulation in oncology, apoptosis assays, and cutaneous T-cell lymphoma models, but biochemical potency and cell-growth IC50 values are assay-dependent.
NMDA: From Excitotoxicity to Ferroptosis Assays
2026-09-19
Explore how NMDA (N-Methyl-D-aspartic acid) connects receptor-driven excitotoxicity with oxidative stress and ferroptosis measurements. This article translates a retinal ganglion cell study into practical assay-design guidance for mechanistic neuroscience research.
Dyngo-4a: A Practical Dynamin Inhibitor Guide
2026-09-18
Dyngo-4a is a research-grade dynamin inhibitor for testing vesicle scission, clathrin-dependent uptake, and cargo trafficking. This guide translates its mechanism into practical dose-response, imaging, neuronal, and lipid nanoparticle mRNA assay workflows while separating established evidence from experimental extensions.
TAI-1: Hec1 Inhibition from Cell Origin to Assay
2026-09-17
TAI-1 is a potent Hec1 inhibitor whose mitotic mechanism can be studied more rigorously when cell state, RB1 biology, and assay design are considered together. This article connects TAI-1 pharmacology with new retinal organoid evidence while defining practical boundaries for cancer research interpretation.
Tropifexor (LJN452) for Reliable FXR Assays
2026-09-16
A scenario-based guide to using Tropifexor (LJN452), SKU BA3602, in FXR, viability, proliferation, and intestinal barrier experiments. It explains concentration planning, DMSO controls, interpretation limits, and practical criteria for selecting a research-grade small molecule.
NMDA for Excitotoxicity and RGC Research
2026-09-16
Use NMDA to create a controlled receptor-mediated injury stimulus for excitotoxicity research, calcium influx measurement, and oxidative stress assay development. A workflow built around fresh dosing, temporal sampling, and BMP4-GPX4 pathway readouts can connect neuronal injury phenotypes with retinal stem-cell and glaucoma model questions.
Q-VD(OMe)-OPh in Mechanism-Resolved Cell Death Assays
2026-09-14
Q-VD(OMe)-OPh enables causal caspase inhibition in apoptosis research rather than relying on viability measurements alone. This guide explains how to use it to distinguish apoptosis from ferroptosis and autophagy in resistant colorectal cancer models, while defining translational limits.
ATS-9R: Precision Gene Delivery for Adipose Research
2026-09-14
ATS-9R, or Adipocyte-targeting sequence-9-arginine, connects Prohibitin-directed tissue recognition with nona-arginine-mediated nucleic acid delivery. This evidence-led article explains the biology, validation strategy, practical parameters, competitive positioning, and translational limits that matter when designing adipose-targeted gene-silencing studies.
Q-VD(OMe)-OPh: Caspase Inhibition Guide
2026-09-11
Q-VD(OMe)-OPh is a broad-spectrum pan-caspase inhibitor for controlled apoptosis assays and cell-death mechanism studies. Its reported nanomolar activity, solvent compatibility, and low-cytotoxicity profile make it useful for apoptosis research, while its selectivity limits must be considered.
Palonosetron and CINV: Evidence and Research Design
2026-09-10
This review examines palonosetron hydrochloride as a long-acting 5-HT3 receptor antagonist for preventing chemotherapy-induced nausea and vomiting. Its main contribution is a translational comparison linking receptor pharmacology, delayed-emesis control, and clinical trial interpretation while emphasizing that pharmacologic differences matter only when they improve patient outcomes.
CFTRinh-172 in Reliable Epithelial Cell Assays
2026-09-10
This scenario-driven guide explains how CFTRinh-172 (SKU B1435) can help researchers separate CFTR chloride transport from cytotoxicity, trafficking, and assay-vehicle effects. It provides practical design, interpretation, storage, and vendor-selection guidance for epithelial cell and secretory-transport studies.
Pentoxifylline, Rolipram, and Macrophage NO
2026-09-09
The reference study showed that Pentoxifylline and rolipram suppress LPS/interferon-γ-induced macrophage nitric oxide production by elevating intracellular cAMP and reducing inducible nitric oxide synthase expression. Its integrated in vitro and in vivo design connects phosphodiesterase inhibition with macrophage regulation while clarifying the substantially greater potency of rolipram.
Brazilin and 3-MA in MGO-Induced Endothelial Injury
2026-09-08
The reference study identifies a DOHH/eIF5A hypusination–AMPK/mTOR axis through which brazilin limits methylglyoxal-induced endothelial autophagy and apoptosis. Its combined use of 3-MA, Compound C, DOHH inhibition, gene silencing, and db/db mice provides a mechanistic framework for interpreting autophagy inhibition in diabetic vascular injury research.